Modified antisense nucleotides complementary to a section of...

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/11 (2006.01) A61K 31/70 (2006.01) A61K 45/06 (2006.01) C07H 21/00 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2288946

The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the Ha-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from abnormal expression of the Ha-ras gene, in particular in combination with chemotherapy and radiotherapy. The modified oligodeoxynucleotide according to the invention has the sequence: 5'-TxAxTxTxCxCxGxTxCxAxT-3'-O-PO2-O-R, wherein X is o or s, with the proviso that x is 4 to 9 times equal to s and o means a phosphodiester internucleoside linkage, s means a phosphorothioate internucleoside linkage, R means a C8-C21 alkyl group, -(CH2-CH2O)n-(CH2)m-CH3 or -CH2-CH(OH)CH2O-(CH2)q-CH3 wherein n is an integer from 1 to 6, m is an integer from 0 to 20 and q is an integer from 7 to 20 and A is 2'- deoxyadenosine, G is 2'-deoxyguanosine, C is 2'-deoxycytidine and T is thymidine.

L'invention concerne un oligonucléotide modifié spécifique, complémentaire d'une section du gène humain Ha-ras et mARN, et son utilisation pour réguler, moduler ou inhiber de manière spécifique, l'expression du gène Ha-ras. L'invention concerne également son utilisation comme produit pharmaceutique pour traiter les conditions provenant de l'expression anormale du gène Ha-ras, en particulier, en association avec la chimiothérapie et la radiothérapie. L'oligodésoxynucléotide modifié, selon l'invention, présente la séquence 5'-TxAxTxTxCxCxGxTxCxAxT-3'-O-PO¿2?-O-R x représente o ou s, à condition que x soit 4 à 9 fois égal à s et o représente une liaison d'internucléoside de phosphodiester, s représente une liaison d'internucléoside de phosphorothioate. R représente un groupe alkyle C¿8-?C¿21?, -(CH¿2?-CH¿2?O)¿n?-(CH¿2?)¿m?-CH¿3? ou -CH¿2?-CH(OH)CH¿2?O-(CH¿2?)¿q?-CH¿3? où n est un nombre entier compris entre 1 et 6, m est un nombre entier compris entre 0 et 20 et q est un nombre entier compris entre 7 et 20 et A représente 2'-désoxyadénosine, G représente 2'-désoxyguanosine, C est 2'-désoxycytidine et T est thymidine.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Modified antisense nucleotides complementary to a section of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified antisense nucleotides complementary to a section of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified antisense nucleotides complementary to a section of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1392241

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.